Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Ann Oncol ; 29(8): 1687-1700, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29924296

ABSTRACT

The European Society for Medical Oncology (ESMO) consensus conference on malignant lymphoma was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (1) the elderly patient, (2) prognostic factors suitable for clinical use and (3) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the questions devised by their group. These recommendations were then presented to the entire multidisciplinary panel and a consensus was reached. This manuscript presents recommendations regarding the management of the following 'ultra-high-risk' situations: (1) early central nervous system relapse of diffuse large B-cell lymphoma, (2) primary refractory Hodgkin lymphoma and (3) plasmablastic lymphoma. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. All expert panel members approved this final article.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma/therapy , Medical Oncology/standards , Neoplasm Recurrence, Local/therapy , Practice Guidelines as Topic , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Antineoplastic Combined Chemotherapy Protocols/standards , Biomarkers, Tumor/analysis , Clinical Trials as Topic , Consensus Development Conferences as Topic , Drug Resistance, Neoplasm , Europe , Humans , Lymphoma/diagnosis , Lymphoma/pathology , Medical Oncology/methods , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/epidemiology , Prognosis , Radiotherapy, Adjuvant/methods , Radiotherapy, Adjuvant/standards , Risk Factors , Societies, Medical/standards , Treatment Outcome
2.
Br J Cancer ; 106(5): 988-95, 2012 Feb 28.
Article in English | MEDLINE | ID: mdl-22315055

ABSTRACT

BACKGROUND: Not all patients have benefited equally from the advances in non-Hodgkin lymphoma (NHL) survival. This study investigates several individual-level markers of socioeconomic position (SEP) in relation to NHL survival, and explores whether any social differences could be attributed to comorbidity, disease and prognostic factors, or the treatment given. METHODS: This registry-based cohort study links clinical data on prognostic factors and treatment from the national Danish lymphoma database to individual socioeconomic information in Statistics Denmark including 6234 patients diagnosed with NHL in 2000-2008. RESULTS: All-cause mortality was 40% higher in NHL patients with short vs higher education diagnosed in the period 2000-2004 (hazard ratio (HR)=1.40 (1.27-1.54)), and 63% higher in the period 2005-2008 (HR=1.63 (1.40-1.90)). Further, mortality was increased in unemployed and disability pensioners, those with low income, and singles. Clinical prognostic factors attenuated, but did not eliminate the association between education and mortality. Radiotherapy was less frequently given to those with a short education (odds ratio (OR)= 0.84 (0.77-0.92)), low income (OR=0.80 (0.70-0.91)), and less frequent to singles (OR=0.79 (0.64-0.96)). Patients living alone were less likely to receive all treatment modalities. CONCLUSION: Patients with low SEP have an elevated mortality rate after a NHL diagnosis, and more advanced disease at the time of diagnosis explained a part of this disparity. Thus, socioeconomic disparities in NHL survival might be reduced by improving early detection among patients of low SEP.


Subject(s)
Health Status Disparities , Healthcare Disparities , Lymphoma, Non-Hodgkin , Adult , Aged , Aged, 80 and over , Cohort Studies , Denmark/epidemiology , Female , Humans , Lymphoma, Non-Hodgkin/epidemiology , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Prognosis , Socioeconomic Factors , Survival , Treatment Outcome
3.
Eur J Cancer ; 38(3): 401-8, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11818206

ABSTRACT

This study presents the first large clinical analysis of 105 unselected mantle cell lymphoma (MCL) patients diagnosed from 1992 to 2000 in a well-defined Danish population. The annual incidences were 0.7/100000 for men and 0.2/100000 for women, with no significant change during the study period. Of 97 evaluable cases, 43% achieved a complete response (CR) after initial therapy. The median disease-free (DFS) and overall survival (OS) rates were 15 and 30 months, respectively. In multivariate analysis, splenomegaly (P=0.002), anaemia (P=0.0001) and age (P=0.002), but not the international prognostic index (IPI) and the Ann Arbor staging system, had an independent impact on survival. Moreover, in a sub-analysis of 45 younger MCL patients (<65 years), a trend towards an OS plateau of 58% was observed in cases without splenomegaly and anaemia (n=29). Thus, in contrast to previously suggested prognostic factors, these variables may prove useful for clinical decisions in a significant subset of MCL patients.


Subject(s)
Lymphoma, Mantle-Cell/mortality , Age Distribution , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Denmark/epidemiology , Disease-Free Survival , Female , Humans , Immunohistochemistry/methods , Immunophenotyping/methods , Incidence , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/pathology , Male , Multivariate Analysis , Neoplasm Staging/methods , Population Surveillance , Prognosis
4.
Eur J Haematol ; 66(3): 143-51, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11350482

ABSTRACT

Platelet-leukocyte adhesion may occur as a consequence of platelet activation and possibly plays a key role in the deposition of activated platelets and fibrin in the thrombotic plug. The aim of the present study was to assess by whole blood flow cytometry the presence of circulating platelet-leukocyte aggregates (PLA) and the platelet-leukocyte response to platelet agonist stimulation (ADP and TRAP) in 50 patients with chronic myeloproliferative disorders (MPD) and 30 controls. PLA were identified as platelet-granulocyte/monocyte aggregates (PGMA), platelet-monocyte aggregates (PMA) and defined as the percentage of leukocytes coexpressing the platelet-specific marker glycoprotein Ib. Compared to controls the mean percentage of PGMA and PMA was increased in unstimulated whole blood from patients with MPD (7.98 vs. 1.76%; p<0.001 and 12.34 vs. 3.2%; p<0.001, respectively). The percentage of PGMA was correlated to the platelet count (r=0.46; p<0.001), percentage of P-selectin (r=0.69; p<0.001) and thrombospondin (r=0.58; p<0.001) positive platelets and platelet expression of GPIV (r=0.33; p=0.02). The mean percentage of PGMA and PMA was significantly increased in ADP-stimulated whole blood of patients (57.14 vs. 47.92%; p=0.009 and 54.91 vs. 45.89%; p<0.001, respectively). Compared to patients without a history of thrombosis, patients having experienced microvascular disturbances or a thrombotic event had a higher mean percentage of PGMA and PMA in non-stimulated whole blood (10.07 vs. 6.34%; p=0.025 and 14.81 vs. 10.48%; p=0.021, respectively) and a higher percentage of PGMA in ADP stimulated whole blood (64.32 vs. 51.50%; p<0.01). These data document an increased frequency of PLA in non-stimulated whole blood in MPD associated with a previous history of thrombosis or microvascular disturbances.


Subject(s)
Blood Platelets/pathology , Leukocytes/pathology , Myeloproliferative Disorders/blood , Platelet Activation , Thrombophilia/blood , Thrombosis/epidemiology , Adenosine Diphosphate/pharmacology , Adult , Aged , Aged, 80 and over , Blood Platelets/drug effects , Cell Adhesion/drug effects , Cell Adhesion Molecules/blood , Cell Aggregation/drug effects , Female , Flow Cytometry , Humans , Leukocyte Count , Male , Middle Aged , Platelet Activation/drug effects , Platelet Aggregation/drug effects , Platelet Count , Proteins/pharmacology , Receptors, Thrombin , Thrombophilia/etiology , Thrombosis/etiology
5.
Leukemia ; 14(10): 1727-35, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11021747

ABSTRACT

The INK4a/ARF locus at chromosome 9p21 encodes two structurally and functionally distinct molecules with tumor-suppressive properties. p16INK4a controls cell cycle progression by inhibiting phosphorylation of the retinoblastoma protein (Rb), while ARF prevents MDM2-mediated degradation of p53. By using a panel of PCR-based methods, we have examined the status of the p16INK4a, ARF and p53 genes in 123 cases of non-Hodgkin's lymphoma (NHL) at diagnosis. Alterations of one or more of these genes were detected in seven of 36 (19%) cases with low- to intermediate-grade histology, and in 35 of 87 (40%) cases with aggressive histology. For the aggressive lymphomas, the Kaplan-Meier estimate of overall survival for cases with disruption of either p16INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5 year survival 45% vs 35%; P= 0.85), suggesting that selective inactivation of one of the pathways does not significantly influence overall survival. By contrast, the 5-year survival was only 7% for cases with concurrent disruption of p16INK4a and the ARF-p53 pathway vs 38% for cases with retention of one or both pathways (P = 0.005). Similar results were obtained when the analysis was confined to diffuse large B cell lymphomas (P= 0.019). On stepwise multivariate regression analysis including factors from the international prognostic index, concurrent disruption of p16INK4a and the ARF-p53 pathway was an independent negative prognostic factor in NHL with aggressive histology (P = 0.006). Our results suggest that the compound status of the p16INK4a and ARF-p53 pathways is a major determinant of outcome in NHL.


Subject(s)
ADP-Ribosylation Factors/genetics , Genes, p16 , Genes, p53 , Lymphoma, Non-Hodgkin/genetics , DNA Methylation , Gene Deletion , Humans , Lymphoma, Non-Hodgkin/pathology , Mutation , Prognosis , Promoter Regions, Genetic , Survival Analysis
6.
Eur J Haematol ; 65(2): 132-9, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10966175

ABSTRACT

In an attempt to characterise the clinical features, incidence and outcome of essential thrombocythaemia (ET) we report our experience in a large unselected series of patients from a well defined region. All new cases of ET in the County of Copenhagen were registered during the period 1977-98. We identified 96 cases of ET, yielding an age- and sex-adjusted annual incidence rate of 0.59/100.000 and a point-prevalence at last follow up of 11/100.000. The overall incidence rate was 0.31 and 1.00 per 100.000 population during the consecutive periods 1977-89 and 1990-98, respectively, corresponding to a 3.2-fold increase. Median age at diagnosis was 67 yr (females 68 yr, males 66 yr, range 18-87 yr), and the female to male (F/M) ratio was 2.6:1. At diagnosis, 52% of the patients displayed no ET-related symptoms and were discovered fortuitously by a routine platelet count. Forty-eight percent presented with thrombohaemorrhagic phenomena, of which microvascular disturbances of the central nervous system (CNS), extremities and skin were most frequently observed (23%). Compared to patients diagnosed after 1989, patients diagnosed before 1990 had a significantly higher mean platelet count, white blood cell (WBC) count, lactate dehydrogenase (LDH) value and alkaline phosphatase value. With a median follow up of 70 months, 5-yr survival was 76%, significantly lower than the expected survival of an age- and sex-matched control group (p = 0.0052). Thirty-seven patients experienced a total of 55 thrombohaemorrhagic events during follow-up, corresponding to an incidence of thrombosis and microvascular disturbances or haemorrhage of 8.1% per pt-yr and 2.5% per pt-yr, respectively. The number of patients experiencing thrombosis or microvascular disturbances was significantly higher among the 29 patients who never received acetylsalicylic acid (ASA) compared to the 67 patients who received ASA during follow up (45% vs. 21%; p = 0.017). This study provides population-based data suggesting the benefit of treatment with low-dose ASA in a non-selected population of patients with ET.


Subject(s)
Thrombocythemia, Essential/epidemiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Denmark/epidemiology , Female , Humans , Incidence , Male , Middle Aged , Multivariate Analysis , Sex Factors , Survival Analysis , Thrombocythemia, Essential/diagnosis , Thrombocythemia, Essential/drug therapy , Treatment Outcome
7.
Br J Haematol ; 110(1): 116-24, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10930987

ABSTRACT

Chronic myeloproliferative disorders (MPDs) are characterized by a high incidence of thrombohaemorrhagic complications, possibly caused by platelet dysfunction. In an attempt to define platelet functional abnormalities, we assessed the expression of activation-dependent membrane proteins in unstimulated and agonist [ADP and thrombin receptor-activating peptide (TRAP)]-stimulated platelets using quantitative whole blood flow cytometry in samples from 50 MPD patients and 30 controls. The receptor densities of activation markers and glycoproteins (GPs) were quantified using standardized fluorescent beads. Compared with controls, the mean percentage of P-selectin-positive (15.3% vs. 7.2%; P < 0.001) and thrombospondin (TSP)-positive (6.6% vs. 3.7%; P = 0.003) platelets was increased in unstimulated platelets from patients. Patients having experienced a thrombotic event had a higher mean percentage of TSP-positive non-stimulated platelets than patients without a history of thrombosis (9.0% vs. 4.6%; P = 0.02) and a higher GPIV molecules of equivalent fluorochrome (MEF) value (33113 vs. 24471 MEF; P = 0.02). Mean MEF values of monoclonal antibodies (mAbs) against GPIb (34055 vs. 38945 MEF; P < 0.001) and GPIIb/IIIa (1416 vs. 1648 MEF; P < 0. 001) were significantly reduced among patients, whereas surface expression of GPIV was increased in patients (28273 vs. 16258 MEF; P < 0.001). In TRAP (10 micromol/l) stimulated whole blood, the MEF of P-selectin (9611 vs. 13293 MEF; P = 0.004) and CD63 (2385 vs. 5177 MEF; P < 0.001) and the ratio of PAC-1/GPIIb/IIIa MEF (0.98 vs. 2. 00; P < 0.001) was reduced in patients, indicating either a reduced granule GP content or an intrinsic cellular defect in receptor-mediated granule secretion and activation of the GPIIb/IIIa complex. Expressed as the relative change of MEF compared with unstimulated platelets, TRAP induced decrease of GPIb (7.8% vs. 45%; P < 0.001) and increase of GPIIb/IIIa (49.1% vs. 95.7%; P < 0.001) and GPIV expression (17.8% vs. 55.2%; P < 0.001) was attenuated in patients.


Subject(s)
Bacterial Proteins , Blood Platelets/metabolism , Membrane Glycoproteins/metabolism , Myeloproliferative Disorders/metabolism , Platelet Activation , Adenosine Diphosphate , Adult , Aged , Aged, 80 and over , Biomarkers/analysis , Case-Control Studies , Female , Flow Cytometry , Humans , Male , Middle Aged , Myeloproliferative Disorders/blood , RNA-Binding Proteins , Transcription Factors
8.
Leuk Lymphoma ; 32(3-4): 365-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10037035

ABSTRACT

The effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on the number of granulocytes in peripheral blood and myeloid cells in the bone marrow were studied in seven patients with chronic lymphocytic leukemia (CLL). The neutrophil count in the peripheral blood rose by a median of 193% (range 142-980%), p = 0.02, and the increase persisted for more than 2 weeks after discontinuation of the treatment. The percentage of myeloid cells in bone marrow increased by 166% (range--57-1800%). In neutropenic CLL patients with recurrent infections GM-CSF treatment may constitute a new treatment modality.


Subject(s)
Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Aged , Female , Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage , Humans , Injections, Subcutaneous , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Middle Aged
9.
Leuk Res ; 22(11): 983-9, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9783799

ABSTRACT

The plasma cell labeling index (PCLI) in patients with multiple myeloma (MM) is relatively low and this has been associated with the low rate of remission following chemotherapy. Interleukin-6 (IL-6) has been demonstrated to be a major growth factor of myeloma cells. In order to increase the S-phase proportion of myeloma cells, which might increase the sensitivity to chemotherapy, we gave rhIL-6 followed by chemotherapy to 15 myeloma patients with refractory disease. A total of 25 treatment cycles were administered since ten patients had two cycles. The rhIL-6 dose was 2.5 (n = 3), 5.0 (n = 6) and 10.0 microg/kg (n = 6) by subcutaneous injection once daily for 5 days and chemotherapy was administered on the last day of rhIL-6 injection. The effect of rhIL-6 treatment on labeling index (LI) was heterogeneous, but no statistically significant change was noted for this particular group as a whole. In two patients an increase (mean 7.7%) in LI of mononuclear bone marrow cells during the rhIL-6 treatment was demonstrated and in one patient a decrease of 2.8% was seen. Assessment of PCLI demonstrated an increase of 2.9% in one out of six patients and a decrease of 1.9% in one out of six patients. None of the 15 patients achieved remission according to standard criteria. During the rhIL-6 treatment, 14 of the 15 patients developed mild constitutional adverse events (AE) well known in patients treated with IL-6, and none of the AE in the subsequent chemotherapy phase were related to IL-6. In conclusion, our study demonstrated that rhIL-6 can be administered safely to patients with refractory MM, but the cell cycle recruitment approach was not sufficiently effective to be of clinical value.


Subject(s)
Antineoplastic Agents/administration & dosage , Interleukin-6/pharmacology , Multiple Myeloma/therapy , Plasma Cells/drug effects , S Phase , Adolescent , Adult , Aged , Cell Count , Female , Humans , Injections, Subcutaneous , Interleukin-6/administration & dosage , Interleukin-6/toxicity , Male , Middle Aged , Multiple Myeloma/drug therapy , Multiple Myeloma/metabolism , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Remission Induction
10.
Leuk Res ; 21(10): 985-95, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9403009

ABSTRACT

Chromosomal abnormalities is one of the most important prognostic factors in acute myeloid leukemia (AML). Other parameters which may influence the prognosis include age, French-American-British-type, clinical variables and possibly the expression of certain immunophenotypic surface makers. However, only rarely has the expression of these markers been analyzed in multivariate models including the information from cytogenetics and clinical variables. We conducted a retrospective study of 117 consecutive adult patients with de novo AML diagnosed and treated in our institution during a 6-year period. Following standard induction chemotherapy with daunomycin and cytosine arabinoside 75 patients (64%) achieved complete remission (CR). The overall 5 year survival rate was 23% and, for patients achieving CR, 30%. When all patients were analyzed age, chromosomal aberration and lack of CD33 expression were of independent prognostic value. The overall 5 year survival rate was 28% for patients aged 55 years or younger, 25% for patients aged 56-65 years and 4% for those > 65 years, P = 0.041. Patients with good-risk chromosomal abnormalities presented an overall 5 year survival of 36%, compared to 25% in patients with normal karyotype, 22% in patients with intermediate risk abnormalities and 5% in patients with poor-risk abnormalities, P = 0.004. Patients with CD33+ myeloblasts had an overall survival of 25% at 5 years compared to 0% in the CD33- patients, P = 0.021. Analysis of the expression of CD7, CD34 and terminal deoxynucleotidyl transferase on myeloblasts had no impact on overall survival in a multivariate analysis. Thus, this study confirmed the prognostic value of age and cytogenetic risk group and defined CD33 as a novel factor of independent prognostic importance in adult de novo AML.


Subject(s)
Chromosome Aberrations , Chromosome Disorders , Immunophenotyping , Leukemia, Myeloid/genetics , Acute Disease , Adult , Aged , Antibiotics, Antineoplastic/therapeutic use , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Antimetabolites, Antineoplastic/therapeutic use , Cytarabine/therapeutic use , Daunorubicin/therapeutic use , Disease-Free Survival , Female , Humans , Karyotyping , Leukemia, Myeloid/immunology , Male , Middle Aged , Multivariate Analysis , Prognosis , Remission Induction , Retrospective Studies , Sialic Acid Binding Ig-like Lectin 3
11.
Ugeskr Laeger ; 159(28): 4389-93, 1997 Jul 07.
Article in Danish | MEDLINE | ID: mdl-9235735

ABSTRACT

Treatment with antibodies in patients with lymphoproliferative diseases was, until recently, limited to phase I studies due to limited response or subsequent development of anti-globulin response. The introduction of the hybridoma technique during the 1970s facilitated large scale production of antibodies, including the development of the Campath rat-antibodies. The epitope was launched against CD52, a glycoprotein present in large amounts on the surface of lymphocytes, and the primary use was in-vitro depletion of bone marrow from allogeneic bone marrow transplantation donors. The development of the human Campath-1H antibody was successful in 1988, leading to minimized anti-globulin response when used in vivo, and large multi-center studies were initiated. In this study we present an overview of the preclinical and clinical experiences with Campath-1H, including data from patients treated with the antibody in our clinic.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neoplasm/therapeutic use , Antineoplastic Agents/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Lymphoma, Non-Hodgkin/therapy , Aged , Alemtuzumab , Antibodies, Monoclonal, Humanized , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphoma, Non-Hodgkin/immunology , Male , Middle Aged
12.
Leukemia ; 11(1): 37-41, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9001416

ABSTRACT

In 1991 we reported the results from a prospective randomised phase 3 trial comparing 7 days continuous infusion of cytosine arabinoside (ara-C) combined with either daunorubicin (DNR) or aclarubicin (ACR) as direct i.v. injection for 3 days as induction chemotherapy (CT) for patients with de novo acute myeloid leukemia (AML) followed by early intensive consolidation CT with two alternating cycles of high-dose ara-C and two cycles of amsacrine plus etoposide, and finally 3 days of daunomycin plus 7 days of ara-C as administered for induction of remission. A total of 174 patients with de novo AML in the age group 17-65 years were included. The patients have now been followed till death or for at least 7 years, and an evaluation of the long-term survival and the risk of developing secondary neoplasms has been made. The overall survival rate 5-years after diagnosis was 23%, and after 10 years 19%. No difference was found between the two treatment regimens in overall survival or disease-free survival (DFS). For the subgroup of 99 patients who achieved complete remission after one or two induction courses, 5- and 10-year survival rates were 35% and 31% respectively, with the highest survival rates in the age group 17-39 years (57% at 5 years) as compared with 27% in patients aged 40-60 years (P= 0.007). Seven secondary neoplasms were diagnosed simultaneously with or after the diagnosis of AML indicating a standardized incidence ratio (SIR) of 3.41, (95% CI: 1.60-7.26). In three cases the secondary neoplasms were diagnosed simultaneously with the AML diagnosis and were for that reason completely unrelated to the chemotherapy administered for AML, as the psammomatous meningeoma diagnosed after only 8 months. The remaining three neoplasms which developed subsequently did not significantly exceed the expected number, with a SIR = 1.46 (0.47-4.57). Thus, no increased risk of solid tumors causally related to the intensive chemotherapy for de novo AML was observed. However, a generally increased risk of solid tumors in patients diagnosed simultaneously with the AML diagnosis seems likely. Over 20% of the patients were alive and in complete remission 5 years after the AML diagnosis, and they have a high probability of surviving the next 5-year period.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Myeloid/drug therapy , Neoplasms, Second Primary/epidemiology , Aclarubicin/administration & dosage , Acute Disease , Adolescent , Adult , Age Factors , Aged , Amsacrine/administration & dosage , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Etoposide/administration & dosage , Female , Follow-Up Studies , Humans , Male , Middle Aged , Recurrence , Remission Induction , Survival Rate , Survivors
13.
Leukemia ; 9(11): 1902-9, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7475282

ABSTRACT

Patients with B cell chronic lymphocytic leukemia (B-CLL) have decreased capacity to mount relevant antibody responses upon immunization, and development of hypogammaglobulinemia is part of the natural history of the disease. We investigated the influence of histamine type-2 (H2) receptor blockade by ranitidine on the in vivo antibody production in B-CLL patients following vaccination. Anti-polysaccharide antibodies in B-CLL patients, vaccinated with a tetanus-toxoid conjugated vaccine against Haemophilus influenzae type-B (Hib), reached long-term protective levels in more than 90% of B-CLL patients randomized to ranitidine treatment, as compared to 43% of the untreated patients (P = 0.024). No difference in the response to vaccination against influenza virus types A and B protein could be detected between the two groups. Plasma histamine levels were 2-fold to 20-fold higher in 23 out of 31 B-CLL patients, compared to normal controls, and these levels showed a significant positive correlation to disease duration. These findings indicate the possibility of improving in vivo antibody production against a highly relevant pathogen in B-CLL patients by histamine type-2 receptor blockade, and the combined finding of an immune-stimulatory effect of ranitidine and increased plasma histamine levels, strongly suggests the involvement of histamine in the pathogenesis of B-CLL immunodeficiency.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Haemophilus Vaccines/immunology , Histamine H2 Antagonists/therapeutic use , Histamine/blood , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Ranitidine/therapeutic use , Adult , Aged , Antibodies, Bacterial/biosynthesis , Cells, Cultured , Female , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Humans , Interleukin-3/blood , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphocyte Activation/drug effects , Male , Middle Aged , Receptors, IgE/metabolism , Vaccination
14.
Acta Paediatr ; 84(3): 316-24, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7780256

ABSTRACT

Survival from cancer in childhood and adolescence was studied in a population-based series of 8312 cases in children aged 0-19 years notified to the Danish Cancer Registry during 1943-87. During the first period (1943-72), 5-year survival rates from all malignant neoplasms increased from 23% (1943-52) to 33% (1963-72). The greatest improvement was seen during the period 1973-87 when 5-year survival rates reached 64% (1983-87). Between 1973-77 and 1983-87, 5-year survival rates increased from 32% to 62% for leukaemia, from 40% to 70% for acute lymphoblastic leukaemia, from 35% to 54% for non-Hodgkin's lymphoma, from 50% to 66% for central nervous system neoplasms and from 25% to 49% for bone tumours. An improvement in 5-year survival rates from Wilms' tumour was seen between 1960 (19%) and 1980 (81%). Up to 1972, the 5-year survival rate from germ-cell neoplasms was approximately 40%; among patients diagnosed in 1983-87, 76% survived for 5-years. Annual lethality decreased by 2.5% for all malignant neoplasms in 1943-72 and by 4.4% in 1972-87. Lethality was similar for boys and girls during the period 1943-72, but was significantly lower for girls subsequently. A marked effect of age at diagnosis was seen in the early registration period, where lethality rate for the age group 0-9 years was substantially higher compared with that in the age group 10-19 years. This inequality persisted only for children less than 2 years of age at the time of diagnosis in the later period.


Subject(s)
Neoplasms/mortality , Adolescent , Adult , Age Factors , Bone Neoplasms/mortality , Central Nervous System Neoplasms/mortality , Child , Child, Preschool , Denmark , Female , Humans , Infant , Infant, Newborn , Kidney Neoplasms/mortality , Leukemia/mortality , Lymphoma, Non-Hodgkin/mortality , Male , Models, Statistical , Neoplasms, Germ Cell and Embryonal/mortality , Registries , Sex Factors , Survival Analysis , Survival Rate , Wilms Tumor/mortality
15.
Eur J Cancer ; 27(8): 958-65, 1991.
Article in English | MEDLINE | ID: mdl-1832903

ABSTRACT

Studies on the possible association between exposures of parents at the time off conception and cancer in their offspring have provided no clear answer. In this large, population-based, record-linkage study, 1747 childhood cancer cases were identified in the Danish Cancer Registry and matched with 8630 population controls. Specific information on the employment held by each parent at the time of conception and during early pregnancy was obtained through record linkages. The most recent job titles of the parents were also supplied. Significantly increased risks for renal cancer (mainly Wilms' tumour) and for osteogenic and soft tissue sarcomas were observed in children in association with mothers' employment in medical and dental care, based on 15 observations and odds ratios (OR) of 2.5-4.0. The risk for cancers at all sites was significantly elevated in children of female nurses (OR = 1.4; n = 75) and of male and female physicians, dentists, dental assistants, veterinarians and pharmacists combined (OR = 1.4; n = 53). Handling of drugs, exposure to anaesthetics and infections during pregnancy are suggested to be potential risk factors. Significantly increased risks were also observed for children of fathers employed in the manufacture of iron and metal structures (OR = 2.2; n = 16), in machine repair workshops (OR = 2.8; n = 6), as machinists (OR = 1.6; n = 47) and as smiths (OR = 1.5; n = 28). The suggestion in earlier studies that exposures to hydrocarbons and lead are risk factors for childhood cancer could not be supported by our analysis. Overall, few associations were observed; it was therefore concluded that parental occupation is not likely to be a major risk factor for childhood cancer.


Subject(s)
Neoplasms/etiology , Occupational Exposure , Parents , Prenatal Exposure Delayed Effects , Adolescent , Adult , Child , Child, Preschool , Denmark , Female , Humans , Kidney Neoplasms/epidemiology , Kidney Neoplasms/etiology , Male , Medical Record Linkage , Neoplasms/epidemiology , Osteosarcoma/epidemiology , Osteosarcoma/etiology , Pregnancy , Risk Factors
16.
Int J Epidemiol ; 18(3): 546-55, 1989 Sep.
Article in English | MEDLINE | ID: mdl-2807656

ABSTRACT

A population-based study was carried out on 5790 tumours in children (aged 0-14 years) diagnosed in the period 1943-1984 in Denmark. Cases were identified from the files of the high-quality National Cancer Registry in which codes for tumours were based solely on topography until the end of 1977. To achieve a uniform data set following the outlines of the International Classification of Diseases for Oncology (ICD-O) coding system used by the Cancer Registry today, all cases of childhood cancer diagnosed prior to 1978 were re-evaluated, and an ICD-O code was applied. Tumours were aggregated into diagnostic groups suitable for analysis and presentation using an internationally agreed scheme, which was designed by the Manchester Children's Tumour Registry and modified recently by the International Agency for Research on Cancer. The average incidence rates for all histological types of childhood cancer combined were 137 per million boys and 111 per million girls, which are close to those reported from the USA but higher than most of the overall figures reported from Europe. The proportions of specific tumours were similar to those observed in other industrialized countries. The well known excess of cancer cases among boys compared to girls was due mainly to the occurrence of 90% more lymphomas, 30% more leukaemias and 15% more tumours of the central nervous system (CNS) among boys. Although significant increases were seen in the subgroups of CNS neoplasms and neuroblastomas (both sexes) and of lymphomas (boys only), no overall increase in childhood cancer was observed during the 42-year period of registration. While the increase in the incidence of CNS tumours was explained at least partly by better cancer surveillance, no interpretation can be offered for the increases seen for neuroblastomas and lymphomas. Our descriptive data suggest that environmental exposures do not play any significant role in the aetiology of the majority of childhood cancers.


Subject(s)
Neoplasms/epidemiology , Adolescent , Age Factors , Child , Child, Preschool , Denmark/epidemiology , Female , Humans , Incidence , Infant , Lymphoma/epidemiology , Male , Neuroblastoma/epidemiology , Population Surveillance , Registries , Sex Factors
17.
Cancer ; 62(7): 1458-62, 1988 Oct 01.
Article in English | MEDLINE | ID: mdl-3416285

ABSTRACT

The risk of nonocular cancer among survivors of retinoblastoma has been investigated in a population-based study in Denmark, 1943 to 1984. None of the survivors had been treated with chemotherapeutic drugs. Forty-eight patients were treated with x-rays, and 102 patients were treated primarily with surgical removal of the eye(s). The overall relative risk (RR) for a new primary cancer was 4.2 (95% confidence limits, 1.1-11.5). In the subgroup of genetic retinoblastoma the risk was 15.4 (95% confidence limits, 2.6-50.8) and in the group of nonhereditary cancer the risk was 1.7 (95% confidence limits, 0.1-8.5). For all retinoblastoma patients the RR of bone cancer was 100 (95% confidence limits, 17-330). Parents not having retinoblastoma themselves were not at increased risk for nonocular cancer.


Subject(s)
Eye Neoplasms/genetics , Neoplasms, Multiple Primary/epidemiology , Population Surveillance , Retinoblastoma/genetics , Adolescent , Adult , Child , Child, Preschool , Denmark , Eye Neoplasms/radiotherapy , Eye Neoplasms/surgery , Female , Humans , Male , Middle Aged , Registries , Retinoblastoma/radiotherapy , Retinoblastoma/surgery , Risk
SELECTION OF CITATIONS
SEARCH DETAIL
...